Fig. 5.

Effects of decitabine on macrophage activation in vivo and in vitro. B16 cells were implanted on day 1. Mice were treated with decitabine, IL-2, and/or ODN1826 for 2 weeks. A group of mice was not treated. a Peritoneal macrophages were harvested on day 24 and tested for cytotoxicity versus B16 targets. Data represent mean ± SD, n = 3 mice per group. b Peritoneal macrophages and c RAW cells were cultured in vitro with 5 μM decitabine without or with 1 or 10 μg ODN1826. After 18 h RNA was isolated for QRT-PCR to assess RQ relative to unstimulated. Data represent mean RQ of ± SD, n = 3. * mean RQ changes >0.5 log compared to without DAC